A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AFICAMTEN COMPARED TO PLACEBO IN ADULTS WITH SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY Department #: 407-303-7556

The purpose of this study is to compare the effects of aficamten and placebo on health status and exercise capacity in participants with nHCM. The safety and tolerability of aficamten at different, increasing dose levels will also be studied. The effectiveness of aficamten and placebo will be compared by measuring your ability to exercise, heart failure symptoms, and the structure of your heart. You will also be asked to complete questionnaires regarding the status of your general health, your nHCM symptoms, and your quality of life. The study will also measure the amount of aficamten in your blood at various times (PK – pharmacokinetics), and the effect the research drug may have on your nHCM.